Compare TransMedics Group Inc (TMDX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Western Alliance Bancorporation — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Western Alliance Bancorporation is far larger — about 3.5× TransMedics Group Inc's market cap, and Western Alliance Bancorporation pays a 2.07% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WAL | |
|---|---|---|
Market Cap | $2.54B | $8.84B |
Sector | Technology | Financials |
52-Week High | $150.42 | $96.08 |
52-Week Low | $61.99 | $66.70 |
Enterprise Value | $2.94B | — |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.43 and net income margin of 25.63%, supported by consistent quarterly earnings outperformance. Recent news highlights Q2 2026 earnings miss but positive corporate recognition and leadership appointments.
Outlook remains positive with analyst consensus price target of $90.67 suggesting 12% upside. Risks include negative operating cash flow and high interest expenses. The bullish analyst sentiment (79% buy ratings) contrasts with technical bearishness, indicating potential value opportunity if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
